DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL-Rearranged.

Slides:

Advertisements

Similar presentations

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways.

Advertisements

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c by Robert M. Cohen, Robert S. Franco, Paramjit K. Khera,

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

Omega-3 Fatty Acid Blood Levels by H. Robert Superko, Scott M. Superko, Khurram Nasir, Arthur Agatston, and Brenda C. Garrett Circulation Volume 128(19):

HOXA9 is required for survival in human MLL-rearranged acute leukemias by Joerg Faber, Andrei V. Krivtsov, Matthew C. Stubbs, Renee Wright, Tina N. Davis,

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Mast cell leukemia by Sophie Georgin-Lavialle, Ludovic Lhermitte, Patrice Dubreuil, Marie-Olivia Chandesris, Olivier Hermine, and Gandhi Damaj Blood Volume.

The PI3K Delta Inhibitor TGR-1202 and Proteasome Inhibitor Carfilzomib Are Highly Synergistic In Killing Human B- and T-Cell Lymphoma Cells by Changchun.

Do HSCs divide asymmetrically?

by Robert F. Todd, Scott D. Gitlin, Linda J. Burns, and

A Prospective Randomized Trial of Buffy Coat Versus CD34-Selected Autologous Bone Marrow Support in High-Risk Breast Cancer Patients Receiving High-Dose.

by Nadine Martel, James Lee, and Philip S. Wells

Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate.

Next-generation leukemia immunotherapy

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy by Georg.

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma by Shaji K. Kumar, Betsy LaPlant,

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Tax fingerprint in adult T-cell leukemia

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Mechanisms of HIV-associated lymphocyte apoptosis

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.

HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells by Takayuki Ikezoe, Eric S. Daar, Jun-ichi.

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models by L. Danielle Johnston, Sarah Knutson, Natalie Warholic, Christine.

Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute.

Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma.

Taking a leaf from the book of oral tolerance

by Sabah Sallah, and Jim Y. Wan

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Malignant Progenitors From Patients With Acute Myelogenous Leukemia Are Sensitive to a Diphtheria Toxin–Granulocyte-Macrophage Colony-Stimulating Factor.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Patients’ priorities in selecting chronic lymphocytic leukemia treatments by Carol Mansfield, Anthony Masaquel, Jessie Sutphin, Elisa Weiss, Meghan Gutierrez,

Volume 20, Issue 1, Pages (July 2011)

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph.

HU for acute treatment of sickle VOC?

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma by Kyle Runckel, Matthew J. Barth, Cory.

Anergy: the CLL cell limbo

Volume 20, Issue 1, Pages (July 2011)

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Hideki Yoshioka, Hiromi Sato, Hiroto Hatakeyama, and Akihiro Hisaka

The BET inhibitor JQ‐1 in combination with the MEK inhibitor PD synergistically impairs cell proliferation and induces apoptosis of NRAS‐mutant.

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras by S. Haihua Chu, Evelyn J. Song,

MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs by Silvia Maifrede, Esteban Martinez, Margaret Nieborowska-Skorska, Daniela.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Volume 2(Supplement 1):1-3

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease by Margaret T. Lee, Meyer Kattan,

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Sickle cells and sickle trait in thrombosis

Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse:

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.

CR-rate ratios with 95% CIs

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Pure red cell aplasia by Robert T. Means Blood

Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in.

Promising Progression Free and Overall Survival Using a Novel (CY/FLU/TBI) Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Sibling Stem Cell.

Presentation transcript:

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL-Rearranged Leukemia Cells by Christine R Klaus, Scott R. Daigle, Dorothy Iwanowics, L. Danielle Johnston, Carly A Therkelsen, Jesse J Smith, Mikel P Moyer, Robert A. Copeland, Edward J Olhava, Margaret Porter Scott, Roy M. Pollock, and Alejandra Raimondi Blood Volume 122(21):3930-3930 November 15, 2013 ©2013 by American Society of Hematology

Figure 1. Fa-CI plots show that EPZ-5676 and cytarabine act synergistically to induce an antiproliferative effect in the Molm-13 cell line in a pre-treatment model. Figure 1. Fa-CI plots show that EPZ-5676 and cytarabine act synergistically to induce an antiproliferative effect in the Molm-13 cell line in a pre-treatment model. (A) Ten-day continuous dosing of EPZ-5676 with addition of cytarabine at day 7 showed a range of fractional effects with CI values <1 denoting synergy. (B) EPZ-5676 was removed at day 7 prior to the addition of cytarabine showing durable combination benefit. Scott R. Daigle et al. Blood 2013;122:3930 ©2013 by American Society of Hematology